VivoSeq
Neurology

ALS (amyotrophic Lateral Sclerosis)

2

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

ALS (Amyotrophic Lateral Sclerosis) is an early-stage landscape with 2 programs across 2 companies. The most active players are Biogen, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Biogen logo

Biogen

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Tofersen

Biogen

Foralumab Nasal

Tiziana Life Sciences LTD

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

3

clinical trials

Not yet recruiting1 · 33%
Available1 · 33%
Recruiting1 · 33%

Clinical Trials

Trial Activity

A Phase 2a Randomized, Double-Blind Study to Evaluate the Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
Not yet recruiting·TTiziana Life Sciences LTD·Phase 2·NCT07688239·44 enrolled
Intermediate-size Patient Population Expanded Access Protocol for Tazbentetol in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Available·SSpinogenix·N/A·NCT07088159
A Study to Evaluate the Biological Effect of Tofersen in Adults With Amyotrophic Lateral Sclerosis Without Mutations in SOD1
Recruiting·WWashington University School of Medicine·Phase 2·NCT07294144·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)